[go: up one dir, main page]

WO2006114805A3 - Utilisation des proteines hmgb2 et hmgb3 pour applications medicales - Google Patents

Utilisation des proteines hmgb2 et hmgb3 pour applications medicales Download PDF

Info

Publication number
WO2006114805A3
WO2006114805A3 PCT/IT2006/000293 IT2006000293W WO2006114805A3 WO 2006114805 A3 WO2006114805 A3 WO 2006114805A3 IT 2006000293 W IT2006000293 W IT 2006000293W WO 2006114805 A3 WO2006114805 A3 WO 2006114805A3
Authority
WO
WIPO (PCT)
Prior art keywords
hmgb2
medical applications
hmgb3 proteins
hmgb3
functional part
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IT2006/000293
Other languages
English (en)
Other versions
WO2006114805A2 (fr
Inventor
Marco Bianchi
Tobias Pusterla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ospedale San Raffaele SRL
Original Assignee
Ospedale San Raffaele SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ospedale San Raffaele SRL filed Critical Ospedale San Raffaele SRL
Publication of WO2006114805A2 publication Critical patent/WO2006114805A2/fr
Publication of WO2006114805A3 publication Critical patent/WO2006114805A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur la protéine HMGB3 ou sur une partie fonctionnelle de celle-ci exerçant une attraction chimique et non une activité proliférative, cette protéine étant destinée à un usage médical et ayant une activité immunostimulatrice. L'invention porte également sur la protéine HMGB2 ou sur une partie fonctionnelle de celle-ci, cette protéine étant utile dans la préparation d'une composition pharmaceutique activant la prolifération cellulaire.
PCT/IT2006/000293 2005-04-28 2006-04-28 Utilisation des proteines hmgb2 et hmgb3 pour applications medicales Ceased WO2006114805A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67550805P 2005-04-28 2005-04-28
US60/675,508 2005-04-28

Publications (2)

Publication Number Publication Date
WO2006114805A2 WO2006114805A2 (fr) 2006-11-02
WO2006114805A3 true WO2006114805A3 (fr) 2007-03-01

Family

ID=36754170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2006/000293 Ceased WO2006114805A2 (fr) 2005-04-28 2006-04-28 Utilisation des proteines hmgb2 et hmgb3 pour applications medicales

Country Status (1)

Country Link
WO (1) WO2006114805A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102899396A (zh) * 2012-07-25 2013-01-30 山东省农业科学院奶牛研究中心 影响奶牛乳腺炎易感/抗性hmgb3基因的核心启动子及其功能性分子标记与应用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5676253B2 (ja) 2008-04-30 2015-02-25 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
JP5660889B2 (ja) * 2008-04-30 2015-01-28 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬
WO2011052668A1 (fr) 2009-10-28 2011-05-05 株式会社ジェノミックス Promoteur de régénération tissulaire utilisant le recrutement de cellules souches mésenchymateuses de moelle osseuse ou de cellules souches pluripotentes dans le sang
KR20130040173A (ko) 2010-03-29 2013-04-23 네이션와이드 칠드런스 하스피탈 인코포레이티드 생물막의 제거를 위한 조성물 및 방법
US20120128701A1 (en) 2010-09-09 2012-05-24 Nationwide Children's Hospital, Inc. Compositions and methods for the removal of biofilms
CN114106139B (zh) 2011-04-26 2024-08-30 斯特姆里姆有限公司 用于诱导组织再生的肽及其应用
AU2013335684B2 (en) 2012-10-25 2017-06-29 Osaka University Novel method for treating cardiac infarction using HMGB1 fragment
RU2649069C2 (ru) 2012-10-25 2018-04-02 Дженомикс Ко., Лтд. Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US10940204B2 (en) 2015-07-31 2021-03-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
BR112019014921A2 (pt) 2017-01-27 2020-03-31 StemRIM Inc. Agente terapêutico para miocardiopatia, infarto antigo do miocárdio e insuficiência cardíaca crônica
JP7596069B2 (ja) 2017-03-15 2024-12-09 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法
JPWO2019107566A1 (ja) 2017-12-01 2020-12-03 株式会社ステムリム 外胚葉性間葉系幹細胞およびその製造方法
WO2019107530A1 (fr) 2017-12-01 2019-06-06 株式会社ステムリム Agent thérapeutique pour une maladie inflammatoire de l'intestin
US20210024594A1 (en) 2018-02-08 2021-01-28 StemRIM Inc. Therapeutic Agent for Psoriasis
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
AU2019354829B2 (en) 2018-10-05 2025-04-17 Research Institute At Nationwide Children's Hospital Hmgb1 protein derivatives for the removal of biofilms

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074337A1 (fr) * 2001-03-16 2002-09-26 Bio3 Research S.R.L. Inhibiteurs et/ou antagonistes de proteines hmgb1 destines au traitement de maladies vasculaires
WO2004046338A2 (fr) * 2002-11-20 2004-06-03 North Shore-Long Island Jewish Research Institute Utilisation de polypeptides hmgb permettant d'accroitre des reponses immunitaires

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074337A1 (fr) * 2001-03-16 2002-09-26 Bio3 Research S.R.L. Inhibiteurs et/ou antagonistes de proteines hmgb1 destines au traitement de maladies vasculaires
WO2004046338A2 (fr) * 2002-11-20 2004-06-03 North Shore-Long Island Jewish Research Institute Utilisation de polypeptides hmgb permettant d'accroitre des reponses immunitaires

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HUTTUNEN HENRI J ET AL: "Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis.", CANCER RESEARCH. 15 AUG 2002, vol. 62, no. 16, 15 August 2002 (2002-08-15), pages 4805 - 4811, XP002394355, ISSN: 0008-5472 *
NEMETH MICHAEL J ET AL: "Hmgb3 deficiency deregulates proliferation and differentiation of common lymphoid and myeloid progenitors.", BLOOD. 15 JAN 2005, vol. 105, no. 2, 15 January 2005 (2005-01-15), pages 627 - 634, XP002394354, ISSN: 0006-4971 *
TERADA ET AL: "Nucleosome regulator Xhmgb3 is required for cell proliferation of the eye and brain as a downstream target of Xenopus rax/Rx1", DEVELOPMENTAL BIOLOGY, ACADEMIC PRESS, NEW YORK, NY, US, vol. 291, no. 2, 15 March 2006 (2006-03-15), pages 398 - 412, XP005338138, ISSN: 0012-1606 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102899396A (zh) * 2012-07-25 2013-01-30 山东省农业科学院奶牛研究中心 影响奶牛乳腺炎易感/抗性hmgb3基因的核心启动子及其功能性分子标记与应用
CN102899396B (zh) * 2012-07-25 2015-02-18 山东省农业科学院奶牛研究中心 影响奶牛乳腺炎易感/抗性hmgb3基因的核心启动子及其功能性分子标记与应用

Also Published As

Publication number Publication date
WO2006114805A2 (fr) 2006-11-02

Similar Documents

Publication Publication Date Title
WO2006114805A3 (fr) Utilisation des proteines hmgb2 et hmgb3 pour applications medicales
WO2006133088A3 (fr) Molecules d'interferons humains ameliorees et utilisations de celles-ci
IL225206A (en) A derivative of multinuclear carbamoylpyridone, its pharmaceutical composition and its use
WO2005074524A3 (fr) Polypeptides de l'interferon humain modifies et leurs applications
WO2007044026A3 (fr) Compositions comportant du collagène modifié et leurs utilisations
IL248917A0 (en) Human anti-23-il antibodies, preparations, methods and uses
UA94221C2 (en) Lipocalin protein
CL2007002017A1 (es) Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
WO2007060117A3 (fr) Proteines effectrices chimeres se liant a la keratine
WO2007109221A3 (fr) Methodes de reduction de l'agregation des proteines
EP2450360A3 (fr) (S)-N-Méthylnaltrexone
WO2006097536A3 (fr) Agonistes a base de peptide dimere contre le recepteur de glp-1
AU2003289641A1 (en) The novel coumarin-amide derivatives and its preparation, said drug composition and its use
EP2360180A3 (fr) Motifs de la famille des polypeptides pancréatiques, polypeptides, méthodes et utilisation de lesdites polypeptides.
IL172507A0 (en) New biological entities and the pharmaceutical or diagnostic use thereof
GEP20115245B (en) Solid preparation
WO2007061939A3 (fr) Dérivés de métabolites de l'inhibiteur de hdac fk228
WO2006097535A3 (fr) Agonistes de peptides de la famille du glucagone presentant une activite similaire a la secretine
IL190460A0 (en) 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
IL187079A0 (en) An oligoadenylate synthetase 1 protein, therapeutic compositions containing the same and screening methods
EP1904845A4 (fr) Résultats et application améliorés d'épreuves de comparaison d'expressions protéiniques
WO2004081027A3 (fr) Anticorps specifiques des neoplasmes et leurs utilisations
WO2006119337A8 (fr) Proteines fluorescentes et leurs utilisations
WO2006017621A3 (fr) Variant d'epissage d'irak1c et son utilisation
AU2003233186A1 (en) Pharmaceutical compositions with anti-tumour activity, in particular for the treatment of leukaemia and glioblastomas

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06728545

Country of ref document: EP

Kind code of ref document: A2